Corporate
Outlook: Stable
Action date: 06/25/2020
Rating action: Upgrade

ATRYS HEALTH SA

Atrys Health focuses its business on the integrated management of cancer disease, specifically in diagnostic activities (personalized treatment/online) and advanced radiotherapy. Currently, the group is in an expansion process by inorganic growth (different corporate acquisitions) and organic growth (continuous investment in R&D projects and agreements with hospital centers). In 2019, the group had (proforma figures) a turnover of € 20.8MM and EBITDA of € 7MM (margin of 33.7%) respectively, also showing a NFD/EBITDA ratio of 3.6x.

Rating

Solicited
Date last rating: 06/25/2020
Date first rating: 07/08/2019